LHU Stock Overview
Develops, manufactures, and markets medical devices and implants used in the field of vascular surgery in the Americas, Europe, the Middle Esat, Africa, and the Asia Pacific. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 5/6 |
| Financial Health | 5/6 |
| Dividends | 4/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
LeMaitre Vascular, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$68.00 |
| 52 Week High | US$102.00 |
| 52 Week Low | US$67.50 |
| Beta | 0.85 |
| 1 Month Change | -13.38% |
| 3 Month Change | -28.80% |
| 1 Year Change | -6.21% |
| 3 Year Change | 66.67% |
| 5 Year Change | 180.99% |
| Change since IPO | 132.72% |
Recent News & Updates
Recent updates
Shareholder Returns
| LHU | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -8.1% | -5.6% | -0.9% |
| 1Y | -6.2% | -14.7% | 14.1% |
Return vs Industry: LHU exceeded the German Medical Equipment industry which returned -11.8% over the past year.
Return vs Market: LHU underperformed the German Market which returned 15.8% over the past year.
Price Volatility
| LHU volatility | |
|---|---|
| LHU Average Weekly Movement | 7.3% |
| Medical Equipment Industry Average Movement | 6.6% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in DE Market | 12.7% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: LHU has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: LHU's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1983 | 658 | George LeMaitre | www.lemaitre.com |
LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery in the Americas, Europe, the Middle Esat, Africa, and the Asia Pacific. The company offers allografts, which are cryopreserved human tissue grafts used in vascular reconstruction, and cardiac repair and reconstruction; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature, as well as human cadaver tissue cryopreservation services. It also provides a suite of biologic products comprising artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches used for vessel closure after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular and porcine patches; carotid shunts that temporarily shunt the blood to the brain; biosynthetic vascular grafts indicated for lower extremity bypass and dialysis access; phlebectomy system for resection and ablation of varicose veins; LifeSpan vascular grafts, which are expanded polytetrafluoroethylene grafts; and vascular grafts used to bypass or replace diseased arteries.
LeMaitre Vascular, Inc. Fundamentals Summary
| LHU fundamental statistics | |
|---|---|
| Market cap | €1.57b |
| Earnings (TTM) | €39.76m |
| Revenue (TTM) | €199.17m |
Is LHU overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LHU income statement (TTM) | |
|---|---|
| Revenue | US$226.26m |
| Cost of Revenue | US$70.60m |
| Gross Profit | US$155.66m |
| Other Expenses | US$110.49m |
| Earnings | US$45.16m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.00 |
| Gross Margin | 68.80% |
| Net Profit Margin | 19.96% |
| Debt/Equity Ratio | 48.3% |
How did LHU perform over the long term?
See historical performance and comparisonDividends
Does LHU pay a reliable dividends?
See LHU dividend history and benchmarks| LeMaitre Vascular dividend dates | |
|---|---|
| Ex Dividend Date | May 15 2025 |
| Dividend Pay Date | May 29 2025 |
| Days until Ex dividend | 10 days |
| Days until Dividend pay date | 4 days |
Does LHU pay a reliable dividends?
See LHU dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/23 14:55 |
| End of Day Share Price | 2025/05/23 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
LeMaitre Vascular, Inc. is covered by 20 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael Petusky | Barrington Research Associates, Inc. |
| Raymond Myers | Benchmark Company |
| Jan Wald | Benchmark Company |